Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Background and Context

The legacy context of general health and science information has historically provided broad, foundational knowledge on topics such as bone health and medication safety. Within this framework, public awareness of bisphosphonate therapies, including Fosamax, has been established primarily through general medical education and patient guidance. This heritage serves as a baseline for understanding therapeutic benefits and routine adverse effects. Transitioning from this general health perspective, a more focused examination emerges regarding occupational exposure concerns. In mass production environments, workers may handle pharmaceutical compounds or their precursors during manufacturing, packaging, or quality control processes. This shift in context moves the discussion from patient-centered medication use to potential workplace exposure scenarios. The concern here is not about therapeutic dosing but about inadvertent contact or inhalation of active ingredients during industrial operations. Such occupational settings require distinct risk assessment frameworks, separate from clinical prescribing contexts. The pivot thus reframes the inquiry: from general health information dissemination to evaluating whether workplace exposure to Fosamax or related compounds could pose specific health risks, such as osteonecrosis of the jaw, in production personnel. This transition maintains a neutral academic tone, avoiding mechanistic claims while highlighting the need for occupational health vigilance in mass production settings.

Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but a serious adverse effect—osteonecrosis of the jaw (ONJ)—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The same association is noted for Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Clinical presentation of ONJ typically involves exposed bone in the maxillofacial region that persists for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, though no single test is definitive. The condition can lead to significant morbidity, including difficulty eating, speaking, and maintaining oral hygiene. The time to onset of symptoms after starting Fosamax varies from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This wide range complicates establishing a precise timeline between exposure and documented harm, as some patients may develop ONJ shortly after initiation while others may not experience symptoms until after prolonged use.

Mechanistic Pathways and Risk Factors

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jaw, which has high remodeling rates, this suppression may impair healing after dental procedures or microtrauma. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone. These mechanisms, combined with local factors such as infection or dental surgery, are thought to contribute to ONJ development. Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Regarding adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes associated risk factors. However, the warning does not quantify the incidence rate or provide specific guidance on monitoring for ONJ beyond clinical awareness. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that ONJ may be a rare event that is difficult to detect in clinical trials. This raises questions about whether the warning adequately conveys the risk to patients and healthcare providers, particularly for those on long-term therapy. Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset, excluding other causes (e.g., cancer, radiation therapy, or other medications), and assessing the presence of known risk factors. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), supporting a causal link. However, ONJ can also occur spontaneously in patients not taking bisphosphonates, complicating individual causation assessments.

Summary and Implications

In summary, Fosamax is associated with ONJ, with evidence from clinical reports and mechanistic studies supporting a causal relationship. The risk is influenced by duration of use, dental procedures, and other factors. Warnings in the prescribing information address this risk but may not fully capture its variability or rarity. Patients and clinicians should weigh the benefits of Fosamax in reducing fracture risk against the potential for ONJ, particularly in those with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax (alendronate) and other bisphosphonates have been reported to cause ONJ as a serious adverse effect, as noted in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms after starting Fosamax varies from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.